News | February 17, 2023
Biocon Q3 FY23 revenue up 36%
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
As per 10th edition of International Diabetes Federation (IDF) Atlas, 2021, India has 74.2 million people with diabetes between the age of 20-79 years
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Subscribe To Our Newsletter & Stay Updated
